Quick answer: Yes. Enclomiphene preserves and can improve fertility, while TRT (exogenous testosterone) reliably suppresses it. This is the most clinically significant difference between the two approaches to low testosterone and is the primary reason many men in their reproductive years choose enclomiphene over TRT.
Does Enclomiphene Preserve Fertility Unlike TRT?
The difference between enclomiphene and testosterone replacement therapy (TRT) in terms of fertility impact is not a matter of degree. It is a fundamental mechanistic divergence that produces opposite outcomes on the male reproductive axis.
Exogenous testosterone, whether delivered by injection, gel, patch, or pellet, tells the hypothalamus and pituitary that circulating testosterone is sufficient or elevated. The brain responds by reducing gonadotropin-releasing hormone (GnRH) pulse frequency. LH and FSH fall to near zero within weeks. Without LH signaling, Leydig cells in the testes stop producing testosterone. Without FSH signaling, Sertoli cells stop supporting spermatogenesis. The result is testicular atrophy and, in most men, azoospermia or severe oligospermia within 3 to 6 months of continuous TRT use. Sperm counts of less than 1 million per milliliter are common. Many men on long-term TRT have no measurable sperm.
Enclomiphene works at the opposite end of this axis. It is a selective estrogen receptor (ER) antagonist at the hypothalamus and pituitary. By blocking estrogen negative feedback at those sites, it allows GnRH pulse frequency to increase. LH and FSH both rise. LH directly stimulates Leydig cell testosterone production. FSH directly stimulates Sertoli cell activity and spermatogenesis. The testes are actively supported, not suppressed. Testicular volume is maintained or increases. Spermatogenesis continues or improves.
What the Clinical Data Shows on Fertility Preservation
The pivotal Phase III trial, Wiehle et al., 2014, doi:10.1111/andr.12150, directly compared enclomiphene to topical testosterone gel in men with secondary hypogonadism. The fertility-related findings were stark. In the enclomiphene group, sperm concentration was maintained throughout the study period and actually increased by approximately 14 percent from baseline to week 16. In the testosterone gel group, sperm concentration fell by approximately 25 percent from baseline, with many subjects approaching or reaching oligospermic thresholds.
Drobnis and colleagues, reporting on fertility-specific endpoints from the Phase III program, confirmed that men treated with enclomiphene maintained or improved sperm concentration, total motile sperm count, and morphology throughout the treatment period. These are the three core parameters used in semen analysis to assess male fertility potential. All three moved favorably with enclomiphene. All three moved adversely with exogenous testosterone.
LH and FSH values tell the same story. In the enclomiphene group, both gonadotropins were elevated, consistent with active HPG axis function. In the testosterone group, both were suppressed, consistent with exogenous androgen feedback.
Who Should Consider Enclomiphene Over TRT for Fertility Reasons
The fertility preservation advantage of enclomiphene matters most in specific contexts. Men who are actively trying to father children should not use TRT without understanding that it will likely render them temporarily infertile during treatment. Recovery of spermatogenesis after TRT cessation is possible but not guaranteed, and typically takes 6 to 24 months. Some men recover fully. Some do not recover to pre-TRT levels, particularly after years of continuous use.
Men planning to father children within the next 1 to 3 years are strong candidates for enclomiphene over TRT, provided their hypogonadism is secondary (central) in origin. Men undergoing IVF or IUI cycles who also have secondary hypogonadism are another clear use case, since FSH elevation supports the spermatogenesis their fertility specialist needs to work with.
Men coming off TRT who want to restore fertility should be aware that enclomiphene can be used as part of a recovery protocol to accelerate HPG axis recovery. By blocking estrogen feedback and raising LH and FSH, it helps restart endogenous testosterone production and spermatogenesis. The typical restart timeframe is 3 months, corresponding to one complete spermatogenesis cycle, though earlier improvement in gonadotropins and testosterone can be seen within weeks.
Dosage Note
Research protocols for fertility preservation use 12.5 to 25 mg per day. Elite Bio Supply provides 50 mg tablets in 5-count packs. Tablets are typically halved or quartered to achieve research doses. For a 3-month research protocol at 25 mg per day, approximately 9 to 10 packs would be required.
Enclomiphene vs TRT: Fertility Impact Comparison
| Factor | Enclomiphene | TRT (Testosterone Replacement Therapy) |
|---|---|---|
| Mechanism | ER antagonist at hypothalamus — raises LH and FSH endogenously | Exogenous testosterone — suppresses LH and FSH via negative feedback |
| LH/FSH | Elevated — HPG axis remains active | Suppressed to near zero within weeks |
| Sperm Count | Maintained or improved (Phase III data: +14% at 16 weeks) | Severely reduced; azoospermia common in 3–6 months |
| Testicular Volume | Maintained or increased | Typically decreases (testicular atrophy) |
| Fertility While on Treatment | Preserved — can conceive during treatment | Essentially eliminated during treatment for most men |
| Recovery After Stopping | Rapid — clears in 2–3 days, axis was never suppressed | Slow — 6 to 24 months; not guaranteed to full recovery |
| Best For | Men with secondary hypogonadism who want or may want children | Men with hypogonadism who are not concerned about fertility |
Frequently Asked Questions
Can enclomiphene be used during an IVF attempt?
Enclomiphene raises both LH and FSH, which are precisely the signals needed to support spermatogenesis during an IVF cycle. For men with secondary hypogonadism who are also the male partner in an IVF cycle, enclomiphene use can improve sperm parameters before and during the cycle. The FSH elevation it produces supports Sertoli cell function, which is directly linked to sperm quantity and quality. This is distinct from gonadotropin injections (FSH or hCG) that some fertility clinics use directly, but the endpoint effects on spermatogenesis overlap substantially.
What happens to sperm if I stop enclomiphene?
Enclomiphene has a short half-life of approximately 10 hours. Within 2 to 3 days of stopping, it clears from the body and estrogen feedback at the hypothalamus and pituitary resumes. GnRH, LH, and FSH return toward baseline over the following weeks. Testosterone and spermatogenesis support also return toward pre-treatment levels. Unlike TRT, there is no suppression-and-recovery cycle: the axis was never suppressed, so there is no hole to climb out of.
Does enclomiphene work for fertility if my testosterone is in the normal range?
The question of whether enclomiphene improves fertility in men with normal testosterone but idiopathic low sperm counts is separate from its use in secondary hypogonadism. The Phase III data focused specifically on men with below-normal testosterone. In men with normal testosterone but poor sperm parameters, the picture is more complex. Some researchers have investigated SERM use in this population, and results vary. For men with secondary hypogonadism and low testosterone, the evidence for fertility preservation with enclomiphene is strong. For isolated male factor infertility with normal testosterone, the evidence is less definitive.
Sourcing Enclomiphene in Canada
Elite Bio Supply ships enclomiphene citrate domestically across Canada. Our product is pharmaceutical grade and third-party tested. For researchers studying fertility-preserving testosterone optimization protocols, our 5-tablet packs allow precise quantity management across research timelines. Bulk ordering for longer protocols is available.
Related Guides
- Enclomiphene for Fertility
- Enclomiphene for Secondary Hypogonadism
- Clomid for Fertility in Men
- Enclomiphene vs TRT: Full Comparison
References
- Wiehle RD et al. (2013). Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial. Fertil Steril. doi:10.1016/j.fertnstert.2013.02.040
- Wiehle RD et al. (2014). Enclomiphene citrate stimulates testosterone production while preventing oligospermia. Fertil Steril. PMID 25044085
- Earl JA, Kim ED (2019). Enclomiphene citrate: a treatment that maintains fertility in men with secondary hypogonadism. Expert Rev Endocrinol Metab. PMID 31063005
- Ramasamy R et al. (2014). Testosterone supplementation versus clomiphene citrate for hypogonadism: an age matched comparison of satisfaction and efficacy. J Urol. PMID 24657837
Researching fertility-preserving testosterone support? View enclomiphene at Elite Bio Supply for current availability and COA documentation.
Elite Bio Supply sells research compounds for research purposes only. This content does not constitute medical advice. Consult a qualified physician before use.